Lillian Benck1, Evan Kransdorf1, Jignesh Patel2. 1. Smidt Heart Institute, Cedars-Sinai Medical Center, 8536 Wilshire Blvd #302, Beverly Hills, CA, 90211, USA. 2. Smidt Heart Institute, Cedars-Sinai Medical Center, 8536 Wilshire Blvd #302, Beverly Hills, CA, 90211, USA. Jignesh.patel@cshs.org.
Abstract
PURPOSE OF REVIEW: Chagas cardiomyopathy is an emerging form of non-ischemic cardiomyopathy in the USA. This review aims to summarize current concepts in pathophysiology, disease transmission, medical therapy, and heart transplantation for patients with chronic Chagas cardiomyopathy. RECENT FINDINGS: The incidence of Chagas cardiomyopathy is increasing in the USA, driven mainly by immigration from countries where Chagas disease is endemic. Chagas cardiomyopathy is a chronic, progressive myocarditis, with hallmark features of biventricular dysfunction, ventricular arrhythmias, thromboembolic complications, and a high risk of mortality. Currently, there is no effective treatment for chronic Chagas cardiomyopathy. Heart transplantation is the only treatment for patients with end-stage Chagas cardiomyopathy, but is associated with unique challenges including risk of reactivation. As the prevalence of Chagas cardiomyopathy increases in the USA, practitioners must be aware of the unique challenges in diagnosis and management that Chagas cardiomyopathy presents.
PURPOSE OF REVIEW: Chagas cardiomyopathy is an emerging form of non-ischemic cardiomyopathy in the USA. This review aims to summarize current concepts in pathophysiology, disease transmission, medical therapy, and heart transplantation for patients with chronic Chagas cardiomyopathy. RECENT FINDINGS: The incidence of Chagas cardiomyopathy is increasing in the USA, driven mainly by immigration from countries where Chagas disease is endemic. Chagas cardiomyopathy is a chronic, progressive myocarditis, with hallmark features of biventricular dysfunction, ventricular arrhythmias, thromboembolic complications, and a high risk of mortality. Currently, there is no effective treatment for chronic Chagas cardiomyopathy. Heart transplantation is the only treatment for patients with end-stage Chagas cardiomyopathy, but is associated with unique challenges including risk of reactivation. As the prevalence of Chagas cardiomyopathy increases in the USA, practitioners must be aware of the unique challenges in diagnosis and management that Chagas cardiomyopathy presents.
Authors: Paul T Cantey; Susan L Stramer; Rebecca L Townsend; Hany Kamel; Karen Ofafa; Charles W Todd; Mary Currier; Sheryl Hand; Wendy Varnado; Ellen Dotson; Chris Hall; Pamela L Jett; Susan P Montgomery Journal: Transfusion Date: 2012-03-08 Impact factor: 3.157
Authors: Fernando Bacal; Christiano Pereira Silva; Edimar Alcides Bocchi; Philippe Vieira Pires; Luiz Felipe P Moreira; Victor Sarli Issa; Silvia Ayub Moreira; Fátima das Dores Cruz; Tânia Strabelli; Noedir Antonio Groppo Stolf; José Antonio Franchini Ramires Journal: Am J Transplant Date: 2005-08 Impact factor: 8.086
Authors: Mahmoud I Traina; Daniel R Sanchez; Salvador Hernandez; Jason S Bradfield; Mohamed R Labedi; Tarik A Ngab; Frank Steurer; Susan P Montgomery; Sheba K Meymandi Journal: Circ Heart Fail Date: 2015-07-23 Impact factor: 8.790
Authors: Juliana F Vasconcelos; Bruno S F Souza; Thayse F S Lins; Letícia M S Garcia; Carla M Kaneto; Geraldo P Sampaio; Adriano C de Alcântara; Cássio S Meira; Simone G Macambira; Ricardo Ribeiro-dos-Santos; Milena B P Soares Journal: FASEB J Date: 2013-08-20 Impact factor: 5.191
Authors: José A Pérez-Molina; Ana Pérez-Ayala; Santiago Moreno; M Carmen Fernández-González; Javier Zamora; Rogelio López-Velez Journal: J Antimicrob Chemother Date: 2009-10-09 Impact factor: 5.790
Authors: E P Kransdorf; L S C Czer; D J Luthringer; J K Patel; S P Montgomery; A Velleca; J Mirocha; P C Zakowski; R Zabner; C R Gaultier; Y Qvarnstrom; T Benedict; F Steurer; E Bosserman; C D Paddock; M Rafiei; J A Kobashigawa Journal: Am J Transplant Date: 2013-10-28 Impact factor: 8.086
Authors: Pauline Brochet; Barbara Ianni; João P S Nunes; Amanda F Frade; Priscila C Teixeira; Charles Mady; Ludmila R P Ferreira; Andreia Kuramoto; Cristina W Pissetti; Bruno Saba; Darlan D S Cândido; Fabrício Dias; Marcelo Sampaio; José A Marin-Neto; Abílio Fragata; Ricardo C F Zaniratto; Sergio Siqueira; Giselle D L Peixoto; Vagner O C Rigaud; Paula Buck; Rafael R Almeida; Hui Tzu Lin-Wang; André Schmidt; Martino Martinelli; Mario H Hirata; Eduardo Donadi; Virmondes Rodrigues Junior; Alexandre C Pereira; Jorge Kalil; Lionel Spinelli; Edecio Cunha-Neto; Christophe Chevillard Journal: Front Immunol Date: 2022-09-29 Impact factor: 8.786